On Tuesday, Climb Bio Inc (NASDAQ: CLYM) opened higher 4.97% from the last session, before settling in for the closing price of $1.81. Price fluctuations for CLYM have ranged from $1.05 to $3.21 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -40.44%. Company’s average yearly earnings per share was noted 47.13% at the time writing. With a float of $62.39 million, this company’s outstanding shares have now reached $68.18 million.
Climb Bio Inc (CLYM) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Climb Bio Inc is 8.50%, while institutional ownership is 65.50%. The most recent insider transaction that took place on Jun 30 ’25, was worth 25,154. In this transaction President and CEO of this company sold 20,618 shares at a rate of $1.22, taking the stock ownership to the 48,132 shares. Before that another transaction happened on Jun 20 ’25, when Company’s SVP, Finance & CAO sold 1,242 for $1.24, making the entire transaction worth $1,540. This insider now owns 18,888 shares in total.
Climb Bio Inc (CLYM) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted 0.04 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.15) by 0.19. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 47.13% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.57% during the next five years compared to -40.44% drop over the previous five years of trading.
Climb Bio Inc (NASDAQ: CLYM) Trading Performance Indicators
Check out the current performance indicators for Climb Bio Inc (CLYM). In the past quarter, the stock posted a quick ratio of 18.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.75, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.84 in one year’s time.
Technical Analysis of Climb Bio Inc (CLYM)
Looking closely at Climb Bio Inc (NASDAQ: CLYM), its last 5-days average volume was 0.37 million, which is a drop from its year-to-date volume of 0.42 million. As of the previous 9 days, the stock’s Stochastic %D was 59.87%.
During the past 100 days, Climb Bio Inc’s (CLYM) raw stochastic average was set at 45.38%, which indicates a significant decrease from 81.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1142 in the past 14 days, which was lower than the 0.1526 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9044, while its 200-day Moving Average is $1.6148. However, in the short run, Climb Bio Inc’s stock first resistance to watch stands at $1.9609. Second resistance stands at $2.0217. The third major resistance level sits at $2.1037. If the price goes on to break the first support level at $1.8181, it is likely to go to the next support level at $1.7361. Now, if the price goes above the second support level, the third support stands at $1.6753.
Climb Bio Inc (NASDAQ: CLYM) Key Stats
There are currently 68,184K shares outstanding in the company with a market cap of 129.55 million. Presently, the company’s annual sales total 0 K according to its annual income of -73,900 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -12,890 K.
